A new stilbene (1) was isolated from the root of Cassia sieberiana D. C. together with thirteen known compounds, one stilbene (2), three flavonoids (3-5), six anthraquinones (6-11), two triterpenes (12-13), and phytosterol (14). Their structures were identified using spectroscopic techniques and by comparison of the spectral data with those previously reported in the literature. Compounds 10 -13 were isolated from C. sieberiana for the first time. Compounds 1, 2 and 3 exhibited significant inhibitory activity on 15-lipoxygenase with IC 50 values of 2.62, 1.27 and 0.98 µM, respectively. Compounds 2 and 3 showed acetylcholinesterase inhibitory activity with IC 50 values of 10.57 and 2.89 µM, respectively.
C. sieberiana D. C. is often used in African traditional medicine preparations. It is used for the treatment of malaria, rheumatism, jaundice, ulcer, fever, diarrhea, aphrodisiacs, general body pain, inflammation conditions and analgesic in dysmenorrhea [1] . C. sieberiana has been listed among popular medicinal plants used as a source of analgesic and anti-inflammatory agents. The aqueous extract from the root is used in the treatment of pain and inflammation [2] , while the aqueous extract of the root has demonstrated significant effect on carrageenan-induced oedema [3] . In the course of chemical investigation of the root of C. sieberiana, we have isolated one new stilbene, cassiberianol A (1) along with thirteen known compounds (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Herein, we report the structural elucidation of the new compound and the biological activity of the isolated compounds.
Cassiberianol A (1) was obtained as a brown powder, m.p. 128-130 °C and showed a molecular ion at m/z 289.1073 [M + H] + by the HR-APCI-MS (calcd for C 16 consisting of 7 methine and two methoxy groups. The above data indicated that compound (1) is a characteristic trans-stilbene. The structure of 1 was further supported by the HMBC correlations ( Figure 1B ) between H-7 and C-1 (δ C 123.9) and between H-8 and C-9 (δ C 139.6). The correlations between the methoxy protons at δ H 3.86, δ H 3.86 with C-10 (δ C 145.8) and C-14 (δ C 148.4), respectively, indicated that the two methoxys were located at C-10 and C-14 respectively. According to the molecular formula and the structural information, three hydroxy groups are present in compound 1 and they are located at C-3, C-5 and C-11. The HMBC correlations between H-12 and C-10 (δ C 145.8), C-11 (δ C 139.9) C-14 (δ C 148.4); between H-13 and C-9 (δ C 139.6), C-11 (δ C 139.9), C-14 (δ C 148.4); between the methoxy protons at δ H 3.86 and C-10 (δ C 145.8), and between the methoxy protons at δ H 3.85 and C-14 (δ C 148.4) further confirmed the location of hydroxy at C-11. Thus compound 1 was identified as 3,3҆ ,5-trihydroxy-2҆ ,6҆ -dimethoxy-stilbene and named cassiberianol A (1).
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The other known compounds were identified by the comparison of their spectroscopic data with those previously reported from literature as; piceatannol (2) [4] , quercetin (3) [5] , kaempferol (4) [6] , dihydrokaempferol (5) [5] , islandicin (6) [7] , chrysophanol (7) [8] , physcion (8) [8] , emodin (9) [9] , aloe emodin (10) [10] , chrysophanol-10,10҆ -bianthrone (11) [11] , lupeol (12) [12] , betulinic acid (13) [13] and stigmasterol (14) [14] .
Inflammation can result from the overproduction of leukotrienes through the enzymatic pathway, known as the lipoxygenase pathway. Lipoxygenase (LOX) is the main enzyme responsible for stereo and regio-specific oxygenation of polysaturated fatty acids containing a 1,4-pentadiene system such as arachidonic acid and linoleic acid to form 1-hydroperoxy-1,4-pentadiene products. These products forms various biologically active lipids that play prominent roles in inflammation, such as influencing immune diseases [15] . Hence, the interruption of the lipoxygenases pathway, thereby inhibiting the production of leukotrienes, may be of great therapeutic value in prevention of certain inflammatory related diseases [16] . Quercetin (3), piceatannol (2) and cassiberianol A (1) all demonstrated strong 15-lipoxygenase inhibitory activity, which could be related to the hydroxy groups present in their structures. Piceatannol (2) which has four hydroxyl groups in its structure was found to be more potent (with IC 50 = 1.27 µM) than cassiberianol A (1) (with IC 50 = 2.62 µM), indicating that the methoxy groups could be responsible for the decrease in the LOX inhibitory activity of cassiberianol A (1) [15] . The anthraquinones (6-9 and 11) and terpenes (12) (13) (14) showed weak enzyme inhibition activity against 15-lipoxygenase. Alzheimer's disease (AD) is a progressive neurodegenerative disorder which affects the ability to think, remember, speak or make decisions [17] . A popular hypothesis that describes the cause of AD is one which has linked the pathogenesis of AD to deficiency in acetylcholine (brain neurotransmitter) in the brain, as a result of the catalytic hydrolysis of acetylcholine by an enzyme called acetylcholinesterase (AChE). Therefore, inhibition of the AChE will increase the level of acetylcholine in the brain [18] . As shown in Table 2 , quercetin (3) exhibited potent acetylcholinesterase (from human erythrocytes) inhibitory activity with an IC 50 value of 2.89 µM among the tested compounds while piceatannol (2) demonstrated significant inhibitory activity with an IC 50 value of 10.57 µM. The observed activity in both quercetin (3) and piceatannol (2) could be attributed to the presence of the orthohydroxy groups in their rings. These groups could form H-bonds to the active site of the enzyme, hence inhibiting the enzyme activity.
Furthermore, the carbonyl group on the ring C of quercetin (3) enhanced its activity [19] . However, the anthraquinones (6-9 and 11) and triterpenes (12) (13) (14) showed weak acetylcholinesterase inhibitory activity.
The cholinergic anti-inflammatory pathway has been described to prevent the production of pro-inflammatory cytokines such as TNF (tumor necrosis factor), thereby preventing the abnormal production of pro-inflammatory cytokines [20] . This pathway involve the release of acetylcholine by the action of the efferent vagus nerve (immune cells) which will then inhibit the production of proinflammatory cytokines, without affecting the production of antiinflammatory cytokines [21] . Therefore, the ability of quercetin (3) and piceatannol (2) to inhibit both 15-lipoxygenase and acetylcholinesterase suggest their potential as target agents for development of anti-inflammatory related diseases.
Experimental

General:
The NMR spectra were recorded on a Bruker Avance instrument, Bruker, Massachusetts, USA, (400 MHz for 1 H and 100 MHz for 13 C), using CDCl 3 or CD 3 COCD 3 as solvent. The IR spectra were taken as KBr pellets or ATR on Perkin Elmer FT-IR spectrometer (Massachusetts, USA). Silica gel 60 (70-230 mesh, for Column chromatography (CC) and 230 -400 mesh, for vacuum liquid chromatography (VLC)) from ASTM, Merck, New Jersey, USA, MCI gel (Mitsubishi Chemical Corporation, Tokyo, Japan) and Sephadex LH-20 (Merck, Darmstadt, Germany) were used. Preparative TLC was performed using precoated aluminum plates coated with silica gel 60 F254 of 0.2 mm thickness. 15-Lipoxygenase, Lipoxygenase inhibitor screening assay kit, (Item No. 760700) was purchased from Cayman chemical Co., acetylthiocholine iodide (AChI), galanthamine hydrobromide, and acetylcholinesterase (AChE) from human erythrocytes were purchase from Sigma-Aldrich. o C and the crude extract (50 g) was suspended in distilled water and partitioned successively with n-hexane, ethyl acetate and butanol, to obtain the n-hexane (2.5 g, 0.25%), ethyl acetate (20.8 g, 2.08%), and butanol (15.7 g, 1.57%) fractions, respectively. The nhexane fraction (2.0 g) was fractionated on silica gel (70 -230 mesh) column chromatography (CC) eluting with a gradient of nhexane -EtOAc (from 1:0 to 0:1) to yield 3 major fractions (CBRH 1 -CBRH 3). Subsequent CC of fraction CBRH 2 (500 mg) gave 4 sub-fractions (Fr.1A-D). Recrystallization of Fr.1B from chloroform/MeOH afforded compound 11 (30 mg, 1.20%). Fraction CBRH 3 (850 mg) was further chromatographed repeatedly to obtain compounds 13 (45 mg, 1.80%) and 14 (32 mg, 1.28%). The EtOAc fraction (20 g ) was applied to a silica gel CC (230 -400 mesh, 300 g) and eluted with n-hexane/EtOAc/MeOH in a gradient manner to give 6 fractions (F1-F6). F2 (5 g) was further purified on silica gel CC using a polarity gradient of hexane/ EtOAc to give compounds 6 (20 mg, 0.10%), 7 (60 mg, 0.30%), 8 (45 mg, 0.23%) and 12 (25 mg, 0.13%). F3 (3.0 g) was further purified by silica gel CC, followed by preparative TLC using hexane -EtOAc (4:1) to A new stilbene from the root of Cassia sieberiana Natural Product Communications Vol. 12 (7) 2017 1097 obtain compound 9 (27 mg, 0.14%). F4 (2.0 g) was separated over an MCI gel (MeOH-H 2 O, from 1:1 to 1:0) column and further purified by Sephadex LH-20 (MeOH, 100%) to obtain compound 1 (15 mg, 0.08%). F5 (4 g) was subjected to silica gel CC, eluted with an increasing polarity of hexane/EtOAc/MeOH and further purified on Sephadex LH-20 with MeOH (100%) to afford compounds 10 (10 mg, 0.05%), 3 (35 mg, 0.18%) and 4 (32 mg, 0.16%). Further purification of F6 (3.0 g) on silica gel CC using EtOAc/MeOH, (1:4) as eluting solvent, followed by MCI gel (MeOH-H 2 O, 9:1) and then Sephadex LH-20 (MeOH, 100%) gave compounds 5 (35 mg, 0.18%), and 2 (40 mg, 0.20%).
15-Lipoxygenase Inhibitory Assay:
The reagents for 15-lipoxygenase were prepared according to the standard protocol (Lipoxygenase inhibitor screening assay kit, Item No. 760700) [22] . The stock buffer was prepared with tenfold dilution to give the assay buffer (0.1 M Tris-HCl, pH 7.4). Developing reagent, which serves as the indicator was prepared by mixing equal volumes of Chromogen 1 and 2 followed by vortexing, then the solution was used within 1 hour of preparation. The 15-lipoxygenase (soybean) (10 μL) was diluted with assay buffer (990 μL) and stored on ice. It was used within 1 hour. Arachidonic acid (25 μL), potassium hydroxide (25 μL, 0.1 M) and HPLC-grade water (950 μL) were all mixed thoroughly and used as the substrate. This prepared arachidonic acid solution (1 mM) was used within 30 min. Samples with percentage of inhibition concentration that exceeded 50% during screening process at 100 μM were chosen for IC 50 test. Stock solutions of tested samples were prepared in MeOH to obtain a working concentration of 100, 10, 1, 0.1 and 0.01 μM in the respective wells. The sample stock solution (10 μL) was added to the lipoxygenase (90 μL), then the reaction was initiated by the addition of arachidonic acid (10 μL). The plate was then shaken for 5 minutes on an orbital shaker, and chromogen solution (100 μL) was added to all wells in a dark condition to stop the action of enzyme catalysis. The plate was incubated for 5 min. and read at 495 nm. Quercetin was used as a positive control in this assay.
Results were expressed as a percentage relative to the initial activity.
Inhibition Concentration (%IC) = [A IA (A S -A BS )/A IA ] × 100%
where A initial activity (A IA ) is the absorbance of reaction mixture containing all reagents except the test sample, A sample (A S ) is the absorbance of reaction mixture of the sample and A blank sample (A BS ) is the absorbance of reaction mixture containing all reagents except enzyme.
Microplate method for Acetylcholinesterase Inhibition:
Acetylcholinesterase (AChE) inhibitory activity of the isolated compounds were assessed by the spectrophotometric method [23] . where, E = activity of the enzyme without test sample; and S = activity of enzyme with test sample. All experiments were performed in triplicate.
